Immunotherapy is a promising treatment for advanced lung cancer.The adoptive cellular immunotherapy using chimeric antigen receptor(CAR)-modified T cells breaks the immune tolerance and shows precise targeting and strong antitumor ability.At present,multiple clinical trials of CAR-T immunotherapy have been carried out for treating lung cancer.However,insertion mutation,tumor lysis syndrome,cytokine storm and other adverse reactions make immunotherapy face great challenge.This paper reviews the biological function and clinical application of CAR-modified T cells in cancer immunotherapy.%免疫治疗有望成为晚期肺癌的新兴治疗模式,其中嵌合抗原受体(chimeric antigen receptor,CAR)修饰T细胞的过继细胞免疫治疗打破了机体免疫系统对肿瘤细胞的免疫耐受,具有精准的靶向性和强大的抗肿瘤能力.目前,国内外已开展多个CAR-T疫苗治疗肺癌的临床试验,但可能出现的插入突变、肿瘤溶解症、细胞因子风暴等不良反应使研究面临巨大的挑战.本文对CAR-T的生物功能及其在肺癌治疗中的临床应用研究进展进行综述.
展开▼
